BioMarin’s Clinical Trial Application For GALNS For Morquio A Syndrome Accepted By The MHRA
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that its application for clinical trial authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, has been accepted by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin expects to initiate a Phase 1/2 clinical trial in the next few weeks.
More: continued here
Filed under: Endocrinology on March 29th, 2009
You must be logged in to post a comment.